Design, synthesis, and evaluation of novel hydrazide and hydroxamate derivatives as potent antileukemic agents with preferential HDAC-2 inhibitory activity over class I isoform
The development of isoform-selective histone deacetylase (HDAC) inhibitors remains a promising frontier for targeted cancer therapy, offering a strategic opportunity to maximize therapeutic efficacy while minimizing the adverse side effects of pan-HDAC inhibition. In this study, we present a novel series of 4-iodo-3-ni...